Product Development of a a Brain Tumor Perfusion Imaging Technology
Department of Health and Human Services
Agency Tracking Number:
Solicitation Topic Code:
Small Business Information
IMAGING BIOMETRICS, LLC
1035 KATHERINE DR, ELM GROVE, WI, 53122
Socially and Economically Disadvantaged:
AbstractDESCRIPTION (provided by applicant): Primary brain tumors are the leading cause of cancer-related deaths in children and the fourth leading cause of cancer-related deaths in people under the age of 54. Recently, a significant increase in the incidence of b rain tumors has been observed in people over the age of 60. Survival for adult primary brain tumors ranges from 8-9 months to 2-3 years despite standard therapies such as surgery, radiation therapy and chemotherapy. The most aggressive brain tumors are tho se characterized by the formation of new blood vessels a process called angiogenesis. Consequently, new drugs that inhibit angiogenesis (i.e. antiangiogenic drugs), are a particularly promising alternative for this patient population. To capitalize on this promise a reliable and reproducible, non-invasive method is needed to efficiently optimize and evaluate new therapeutic approaches to brain tumors. Dynamic susceptibility contrast (DSC) MRI methods, which allow the creation of relative cerebral bl ood volume (rCBV), cerebral blood flow (CBF) and mean transit time (MTT) maps, have the potential to fulfill this promise. However, despite the widespread and well-published potential, the clinical adoption rate of DSC studies in brain tumors has been impe ded. This has been attributed to the lack of one or two generally accepted methods for use in brain tumors. To address this issue a DSC comparison study was performed in the laboratory of Dr. Schmainda (co-investigator on this grant). This study was design ed to directly compare, in brain tumor patients, the most commonly used and published DSC acquisition and analysis methods. The results of this study demonstrate that there are two (of 26 tested) approaches that appear to be the most accurate and reliable. The first approach uses currently available MR imaging sequences and a post- processing correction algorithm. The 2nd approach is a new approach, which was developed as a result of the understanding derived from the comparison study. This approach, for wh ich Imaging Biometrics has a patent pending, entails using a dual-echo SPIRAL imaging sequence in combination with a post-processing correction algorithm. These two approaches form the core of the perfusion technology that Imaging Biometrics LLC proposes t o develop. The overall goal is to make this software user-friendly and widely available to both the research and clinical community. To accomplish this goal the following two specific aims will be addressed: Aim 1: To convert the research laborator y code into code that is compliant with industry and FDA standards. The approach will be to rewrite the currently available post-processing software, developed for research purposes, into a base library using platform-independent C/C++. Aim 2: To adapt the software to plug into an existing vendor s viewing and display workstation. The approach will be to implement the appropriate software interfaces to allow the post- processing software in the base library of Aim 1 to be integrated as a feature into open-s ource and commercial image viewing software. Addressing these aims will enable the translation of robust perfusion technologies from the laboratory into the clinic. Ultimately, this should aid in the discovery of new drugs and therapeutic strategies that c an be adapted on a per-patient basis.
* information listed above is at the time of submission.